. Author manuscript; available in PMC: 2007 Oct 21.

Published in final edited form as: Endocrinology. 2005 Aug 11;146(11):4887–4897. doi: 10.1210/en.2005-0572

TABLE 1.

Body weight, soleus muscle weight, L₀, CSA, and soleus muscle weight to body weight ratio (n = 7–8) in different treatment groups

	Intact + Veh	ORX + Veh	ORX + S-4 (3 mg/kg)	ORX + S-4 (10 mg/kg)	ORX + DHT (3 mg/kg)
Body weight (g)	437 ± 14^a	380 ± 33^b	406 ± 31^b	406 ± 19^b	403 ± 14^b
Soleus muscle (mg)	161 ± 14^a	144 ± 11^b	159 ± 18	147 ± 12	155 ± 23
Soleus muscle weight/body weight (mg/g)	0.37 ± 0.03	0.38 ± 0.03	0.39 ± 0.04	0.36 ± 0.03	0.38 ± 0.05
Soleus muscle L₀ (mm)	27.9 ± 1.2^a	25.0 ± 1.9^b	27.3 ± 2.1^a	27.9 ± 1.2^a	26.8 ± 1.2^a
Soleus muscle CSA (mm²)	7.0 ± 0.8	7.0 ± 0.7	7.2 ± 0.4	6.6 ± 0.7	6.9 ± 0.6

Data are presented as mean ± SD.

P < 0.05, compared with the vehicle-treated ORX group.

P < 0.05, compared with the intact control group.